FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to a combination for treating prostate cancer, comprising (i) one of a benzoheterocyclic compound, a pharmaceutically acceptable salt thereof, a stereoisomer, an isotopic compound and (ii) a androgen receptor path modulator, and in some embodiments further comprising an agent selected from abiraterone, abiraterone acetate, galeterone, ODM201, prednisone or combinations thereof, as well as to a pharmaceutical composition and kit for treating prostate cancer, use of said compounds in preparing a medicament for preventing and/or treating prostate cancer, and to a method of preventing and/or treating prostate cancer.
EFFECT: inventions of the group provide inhibition of prostate cancer more effectively.
16 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING PROSTATE CANCER, USING BENZOHETEROCYCLIC COMPOUND AND METHOD FOR PREVENTING AND/OR TREATING PROSTATE CANCER | 2016 |
|
RU2705576C2 |
| COMBINATION, USE THEREOF AND METHOD OF TREATING | 2017 |
|
RU2731535C1 |
| COMBINATION TREATMENT OF CANCER | 2012 |
|
RU2640485C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| BISPHENOL DERIVATIVES AND THEIR USE AS ACTIVITY MODULATORS OF ANDROGEN RECEPTOR | 2017 |
|
RU2767257C2 |
| QUINAZOLINONE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2017 |
|
RU2730500C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| GUANIDINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING NAMPT | 2011 |
|
RU2593759C2 |
| COMBINATION THERAPY INCLUDING AN ACYLTHIOUREA COMPOUND AND ABIRATERONE | 2019 |
|
RU2806635C2 |
| CANCER TREATMENT METHODS | 2019 |
|
RU2811406C2 |
